Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.66 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 2/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.47 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2422195 | 0.92 | KDM4E (0.57) | CHRNB2CHRNA4KDM4EALDH1A1LMNA | |
| SCHEMBL11956181 | 0.85 | CHRNB2 (0.63) | CHRNB2CHRNA4KDM4EALDH1A1LMNA | |
| SCHEMBL781665 | 0.83 | KEAP1 (0.70) | CHRNB2CHRNA4KDM4EALDH1A1LMNA | |
| SCHEMBL3624812 | 0.82 | MAPT (0.56) | CHRNB2CHRNA4KDM4EALDH1A1LMNA | |
| SCHEMBL10602833 | 0.82 | TSHR (0.54) | KDM4EALDH1A1SMN1; SMN2GPBAR1CYSLTR1 | |
| SCHEMBL16902876 | 0.82 | TSHR (0.54) | KDM4EALDH1A1SMN1; SMN2GPBAR1CYSLTR1 | |
| SCHEMBL11245203 | 0.82 | LTA4H (0.59) | CHRNB2CHRNA4KDM4EALDH1A1LMNA | |
| SCHEMBL15472404 | 0.81 | CHRNB2 (0.82) | CHRNB2CHRNA4KDM4EALDH1A1LMNA | |
| SCHEMBL26731059 | 0.81 | KDM4E (0.62) | CHRNB2CHRNA4KDM4EALDH1A1LMNA | |
| SCHEMBL2933175 | 0.81 | KMT2A (0.56) | KDM4EALDH1A1FAAHSMN1; SMN2GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020155879-A1 | COMPOUND CONTAINING BENZYL STRUCTURE AND USE THEREOF | 广州同隽医药科技有限公司 | 2020-08-06 | — | — | WO | disclosed |
| US-9624239-B2 | Protein kinase inhibitors | PHARMASCIENCE INC. (CA) | 2017-04-18 | — | — | US | disclosed |
| US-20140045833-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2014-02-13 | — | — | US | disclosed |
| WO-2012135944-A9 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE INC. (CA) | 2014-01-09 | — | — | WO | disclosed |
| EP-2401270-B1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2013-10-16 | — | — | EP | disclosed |
| EP-2401270-B1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-8507543-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2013-08-13 | — | — | US | disclosed |
| US-8507543-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2013-08-13 | — | — | US | disclosed |
| US-8507543-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2013-08-13 | — | — | US | disclosed |
| US-20130030031-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| WO-2012135944-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE INC. (CA) | 2012-10-11 | — | — | WO | disclosed |
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
| EP-2401270-A1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010097395-A1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010097395-A1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
| US-20100216860-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216860-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216860-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | CCR4, CCR3, CCR1 | CHRNB2 2023/4885CHRNA4 574/4885KDM4E 2789/4885 |
| US-20140045833-A1 | Protein Kinase Inhibitors | LCK, BTK, TEC | CHRNB2 2484/4885CHRNA4 3092/4885KDM4E 1287/4885 |
| US-20130030031-A1 | Novel Compounds | CYP3A4, CYP3A43, ABCG2 | CHRNB2 3568/4885CHRNA4 4072/4885KDM4E 3276/4885 |
| US-20100216860-A1 | NOVEL COMPOUNDS | CYP3A4, CYP3A43, ABCG2 | CHRNB2 3568/4885CHRNA4 4072/4885KDM4E 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.